Partners Biogen Idec and AbbVie are touting late-stage results for their new, monthly multiple sclerosis treatment, preparing to hand in regulatory applications next year and contend in a crowded market.
Oxygen Biotherapeutics' rollercoaster development of a brain injury treatment has come to a grinding halt, as the biotech has put an end to a mid-stage trial on the drug and is looking to move on.
About a year ago Merck KGaA made the controversial decision to revive its late-stage program for the cancer vaccine Stimuvax, trying to start off fresh by renaming it tecemotide and pointing it toward a subpopulation of non-small cell lung cancer patients which appeared to respond in its very big failed Phase III. Today, the program is--once again--officially terminated.
Novartis is contributing $20 million to build a new, 30,000-square-foot research center at Penn that will concentrate on developing a wave of new immuno-oncology drugs.
Novo Nordisk convinced a group of FDA advisers that its liraglutide, already a blockbuster diabetes treatment, can effectively combat obesity, clearing the way for a second indication that could add $1 billion to its annual sales.
Google's stealthy biotech upstart Calico announced today that it has inked its first licensing pact with UT Southwestern in Dallas to gain development rights to protective P7C3 compounds that appear to guard against Parkinson's disease, amyotrophic lateral sclerosis and depression and set up labs in the Dallas area to support its development program.
First there was AbbVie, the new biopharma company created by the big Abbott split. And now comes Baxalta, the new moniker for Baxter's drug spinoff, which is reportedly plotting a big move to the Boston/Cambridge hub.
In this week's EuroBiotech Report, the search for the drug that can do to hepatitis B what Sovaldi does to hepatitis C led OnCure BioPharma to Sweden to strike a $150 million (€116 million) deal with NeuroVive Pharmaceutical. And more.
Menlo Park, CA's Virobay is lining up for a Wall Street debut, filing to bank $50 million in an IPO and accelerate its pipeline of treatments for pain and autoimmune diseases.
Despite an FDA rejection and changing winds in the field of multiple sclerosis, Sanofi believes its Genzyme unit is on an upward trajectory, talking up potential deals and could-be blockbusters for its pricey acquisition.
More than three long years after Orexigen was turned back at the FDA and forced to do a costly late-stage safety study of its weight drug Contrave, the agency has come back and given its seal of marketing approval to the drug.
A long, rough patch in Fragile X syndrome drug R&D just got longer and rougher. Roche has notified patient groups that both of its mid-stage studies for RG7090--an mGluR5 therapy--failed to hit the primary and secondary goals, prompting the pharma giant to shut down the program.
As government health agencies and industry players ramp up efforts to bring experimental therapies as quickly as possible to people affected by the Ebola outbreak in West Africa, the Bill and Melinda Gates Foundation said Wednesday that it is putting up $50 million to aid drug development and outbreak response efforts.
NPS Pharma is moving toward FDA approval with its treatment for a rare disease, as agency staff applauded the drug's efficacy ahead of a make-or-break panel vote.
Xenon Pharmaceuticals has gone 8 long years since its last equity raise, relying on a slate of partnerships with some of the biggest names in the business to fund its work. And now it's set out to test the fall biotech IPO market with a $52 million offering designed to take the company down another stage of its journey through the clinic.
A group of FDA advisers voted against recommending approval for a new combination blood-pressure treatment from Actavis, clouding the future of a prospect the company picked up in its $28 billion buyout of Forest Laboratories.
Genmab is taking its cancer drug collaboration with Seattle Genetics one more step forward. The Danish biotech is handing over an $11 million upfront and promising up to $200 million more to get the right to use Seattle Genetics' antibody-drug conjugate technology for its HuMax-AXL program.